How bioluminescence-based approaches are transforming antimicrobial pharmacodynamics beyond the MIC

Antimicrobial resistance is rising rapidly, and traditional minimum inhibitory concentration (MIC) testing can no longer keep pace with the complexity of real‑world infections. Because MIC methods rely on slow, end‑point measurements, they often miss early metabolic changes, delayed killing, and adaptive regrowth that shape treatment outcomes.

Bioluminescence‑based approaches, including engineered reporter strains like IVISbrite™ Pseudomonas aeruginosa Xen41 (Revvity Inc.), emit light as a direct readout of metabolic activity, allowing researchers to track antimicrobial effects in real time before visible growth changes occur. Recent studies show that these assays not only align with traditional MIC and MBC results but also reveal deeper pharmacodynamic insights, including nutrient‑dependent shifts in antibiotic sensitivity that standard testing cannot predict.

For a fuller understanding of these findings and their implications, explore the literature review.